Immunohistochemical findings in primary fallopian tube cancer. Case report

Primary fallopian tube carcinoma is a rare malignancy, representing about 1% of female genital tract malignancies. We present a case report and compare the medical performance with accessible data from the literature as well as present immunohistochemical analysis of estrogen, progesterone, and proliferative together with basic cytokeratin reactions. We found that immunohistochemical expression of ER-β was dominant over ER-α which encourages further evaluations to be performed on a larger number of samples, especially taking into account the very scant progesterone receptor expression we noted. On the basis of the course of disease under study, etiological problems and the possibility of clinical misdiagnosis have been discussed. The low prevalence rate and lack of clear symptoms of this type of carcinoma makes the final clinical diagnosis almost impossible without an intraoperative histopathological study. Multicenter studies are needed to improve the understanding of possible risk factors.

Primary fallopian tube cancer; Oncogenes; ERα; ERβ; CK7; CK20.

[1] Juretzka M., Hensley M.L., Tew W., Konner J., Aghajanian C., Leitao M. et al.: “A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission”. Eur. J. Gynaecol. Oncol., 2008, 29, 568.

[2] Nappi L., Indraccolo U., Matteo M., Rosenberg P., Greco P.: “Malignant mixed mullerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report”. Eur.J. Gynaecol. Oncol., 2007, 28, 511.

[3] Stewart S.L., Wike J.M., Foster S.L., Michaud F.: “The incidence of primary fallopian tube cancer in the United States”. Gynecol. Oncol., 2007, 107, 392.

[4] Moore K.N., Moxley K.M., Fader A.N., Axtell A.F., Rocconi R.P., Abaid L.N. et al.: “Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary”. Gynecol. Oncol., 2007, 107, 398.

[5] Verit F.F., Kafali H.: “Primary carcinoma of the fallopian tube mimicking tubo-ovarian abscess”. Eur. J. Gynaecol. Oncol., 2005, 26, 225.

[6] Riska A., Leminen A.: “Updating on primary fallopian tube carcinoma”. Acta Obstet. Gynecol. Scand., 2007, 86, 1419.

[7] Mahajan N.N.: “Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation”. Cancer, 2007, 110, 2819.

[8] Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E. et al.: “Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction”. J. Clin. Oncol., 2007, 25, 3985.

[9] Nowee M.E., Dorsman J.C., Piek J.M., Kosma V.M., Hamalainen K., Verheijen R.H.M., Van Diest P.J.: “HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study”. Histopathology, 2007, 51, 666.

[10] Brandenberger A.W., Tee M.K., Jaffe R.B.: “Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues”. J. Clin. Endocrinol. Metab., 1998, 83, 1025.

[11] Pujol P., Rey J.M., Nirde P., Roger P., Gastaldi M., Laffargue F. et al.: “Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis”. Cancer Res., 1998, 58, 5367.

[12] Baker P.M., Oliva E.: “Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update”. Int. J. Gynecol. Pathol., 2005, 24, 39.